Reuters
Published Jul 07, 2023 02:28PM ET
(Reuters) - Eisai Co (OTC:ESAIY) Ltd and Biogen Inc (NASDAQ:BIIB)'s Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food and Drug Administration's standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past.
The following is a list of companies that are currently developing treatments that aim to modify the memory-robbing disease:
Company Drug or Stage of Mechanism
Therapy development &
indication
Eli Lilly (NYSE:LLY) donanemab Designed to
and Co Late-stage trial target toxic
for early protein plaque
Alzheimer’s in the brain
known as
beta-amyloid
and remove
brain plaques
to slow
cognitive
decline
BioVie Inc NE3107 An oral small
Late-stage trial molecule that
for mild to aims to inhibit
moderate neuroinflammati
Alzheimer’s on and insulin
resistance
AB Science masitinib An oral
SA Late-stage study tyrosine kinase
for inhibitor that
mild-to-moderate targets immune
Alzheimer’s cells
responsible for
neuroinflammati
on
Annovis buntanetap An
Bio Inc Mid-to-late-stage orally-administ
trial for moderate ered small
Alzheimer's molecule
inhibitor of
several
neurotoxic
proteins
Cognition CT1812 Oral drug
Therapeuti Mid-stage trial designed to
cs Inc for bind to a
mild-to-moderate specific
Alzheimer’s receptor in
brain cells,
which mediates
the attachment
of beta-amyloid
Coya COYA 301 Designed to
Therapeuti Mid-stage trial inhibit
cs Inc for molecules
mild-to-moderate responsible for
Alzheimer’s neuroinflammati
on and improve
cognitive
function
Actinogen xanamem Blocks
Medical Mid-stage trial production of a
Limited for mild-moderate hormone linked
Alzheimer's to stress
called cortisol
inside brain
cells and is
associated with
cognitive
impairment
AC Immune ACI-24.060 Early- An
SA -to-mid stage antibody-based
trial for immunotherapy
Alzheimer’s vaccine
designed to
target beta
amyloid plaques
Biogen Inc BIIB080 An antisense
Mid-stage trial oligonucleotide
for early-stage therapy
Alzheimer’s directed
against "tau"
proteins
Longeveron lomecel-B A cell therapy
Inc Mid-stage trial designed to
for mild stimulate
Alzheimer’s neuroregenerati
on and prevent
disease
progression
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.